Patents by Inventor Dina N. ALCORN

Dina N. ALCORN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20210139554
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Application
    Filed: October 7, 2020
    Publication date: May 13, 2021
    Applicant: Amgen Inc.
    Inventors: Eric Alan BUTZ, Christy Ann THOMSON, Marc Alain GAVIN, Ian Nevin FOLTZ, Dong XIA, Dina N. ALCORN, Randal Robert KETCHEM, Ai Ching LIM, Kathy MANCHULENKO, Laura SEKIROV, Kelly Ann BERRY, Cyr Clovis Chua DE IMUS, Neeraj Jagdish AGRAWAL, Gunasekaran KANNAN, Li LI
  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 10851144
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: December 1, 2020
    Assignee: Amgen Inc.
    Inventors: Eric Alan Butz, Christy Ann Thomson, Marc Alain Gavin, Ian Nevin Foltz, Dong Xia, Dina N. Alcorn, Ai Ching Lim, Randal Robert Ketchum, Kathy Manchulenko, Laura Sekirov, Kelly Ann Berry, Cyr Clovis Chua De Imus, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Li Li
  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20200024319
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Application
    Filed: May 4, 2016
    Publication date: January 23, 2020
    Applicant: AMGEN INC.
    Inventors: Eric Alan BUTZ, Christy Ann THOMSON, Marc Alain GAVIN, Ian Nevin FOLTZ, Dong XIA, Dina N. ALCORN, Ai Ching LIM, Randal Robert KETCHUM, Kathy MANCHULENKO, Laura SEKIROV, Kelly Ann BERRY, Cyr Clovis Chua DE IMUS, Neeraj Jagdish AGRAWAL, Gunasekaran KANNAN, Li LI